Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1 to 50 of 122

TitleReference numberPublishedLast updated
3C Patch for treating diabetic foot ulcersHTG615
AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomasMIB294
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal)TA793
Antimicrobial prescribing: eravacycline for complicated intra-abdominal infections in adultsES40
Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infectionsES39
Atidarsagene autotemcel for treating metachromatic leukodystrophyHST18
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapyTA788
Belimumab for treating active autoantibody-positive systemic lupus erythematosusTA752
Bladder EpiCheck for detecting bladder cancer recurrenceMIB293
Brain tumours (primary) and brain metastases in over 16sQS203
Cabotegravir with rilpivirine for treating HIV-1TA757
Cemiplimab for treating advanced cutaneous squamous cell carcinomaTA802
ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infectionsHTG602
Colorectal cancerNG151
Colorectal cancerQS20
d-Nav insulin management app for type 2 diabetesMIB285
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitableTA763
Daratumumab monotherapy for treating relapsed and refractory multiple myelomaTA783
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)TA771
Depression in adults: treatment and managementNG222
Diabetes in children and young peopleQS125
Diroximel fumarate for treating relapsing–remitting multiple sclerosisTA794
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA779
Dupilumab for treating severe asthma with type 2 inflammationTA751
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiationTA798
EarlyCDT Lung for assessing risk of lung cancer in solid lung nodulesHTG611
Elosulfase alfa for treating mucopolysaccharidosis type 4AHST19
Empagliflozin for treating chronic heart failure with reduced ejection fractionTA773
Endo-SPONGE for treating low rectal anastomotic leakHTG605
Endoanchoring systems in endovascular aortic aneurysm repairHTG625
Endobronchial nerve ablation for chronic obstructive pulmonary diseaseHTG604
Endoscopic balloon dilation for subglottic or tracheal stenosisHTG614
Endoscopic full thickness removal of gastrointestinal stromal tumours of the stomachHTG612
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal)TA797
Faricimab for treating diabetic macular oedemaTA799
Faricimab for treating wet age-related macular degenerationTA800
Fetal alcohol spectrum disorderQS204
Filgotinib for treating moderately to severely active ulcerative colitisTA792
Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment)HTG619
FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndromeMIB281
Fremanezumab for preventing migraineTA764
Glaucoma: diagnosis and managementNG81
Gout: diagnosis and managementNG219
Granulox for managing chronic non-healing woundsMIB296
Ibrutinib for treating Waldenstrom's macroglobulinaemiaTA795
icobrain ms for active relapsing–remitting multiple sclerosisMIB291
Integrated health and social care for people experiencing homelessnessNG214
Intramedullary distraction for lower limb lengtheningHTG613
Intramedullary distraction for upper limb lengtheningHTG621
Joint replacement (primary): hip, knee and shoulderQS206

Results per page

  1. 10
  2. 25
  3. 50
  4. All